How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

851 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy

Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy Prescrire IN ENGLISH - Spotlight ''Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy '', 1 March 2017 {1} {1} {1} | | > > > Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy FEATURED REVIEW Graves' disease is the most frequent cause of hyperthyroidism. What is the best treatment for adults with Graves' disease? To answer this question, we reviewed the literature using the standard Prescrire methodology. Full review (6 pages) available for download by subscribers. Abstract What is the best treatment for adults with Graves

2017 Prescrire

2. Effect of Antithyroid Therapies on Bone and Body Composition: A Prospective, Randomized, Clinical Study Comparing Antithyroid Drugs with Radioiodine Therapy. (PubMed)

Effect of Antithyroid Therapies on Bone and Body Composition: A Prospective, Randomized, Clinical Study Comparing Antithyroid Drugs with Radioiodine Therapy. Thyrotoxicosis is associated with loss of body weight and bone mineral content (BMC). Antithyroid drugs (ATD) and radioiodine therapy (RIT) are the common options for the management of thyrotoxicosis. We evaluated the effect of ATD and RIT on BMC and body composition.In this prospective study, we randomized 60 patients of thyrotoxicosis

2019 Indian journal of endocrinology and metabolism Controlled trial quality: uncertain

3. A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment (PubMed)

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD (...) for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.

Full Text available with Trip Pro

2018 Clinical Case Reports

4. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. (PubMed)

Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Untreated or insufficiently treated Graves disease in pregnancy may pose risks to both mother and fetus. Antithyroid drugs (ATDs) are the treatment mainstay, but the potential teratogenic effect of these drugs has prompted clinicians to question the safe management of this vulnerable population.To examine the association between maternal prescriptions for ATDs and congenital malformations in live births.Nationwide

2018 Annals of Internal Medicine

5. Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report (PubMed)

Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report Graves thyrotoxicosis rarely presents with painless jaundice resulting from hyperthyroidism-associated hepatotoxicity, without preexisting liver disease. Management in patients with this presentation is challenging, given that the thionamides, methimazole and propylthiouracil, have both been associated with drug-induced liver injury. Radioactive iodine ablation and thyroidectomy are well

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

6. Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? (PubMed)

Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? Resistance to thyroid hormone β (RTHβ) due to homozygous THRB defects is exceptionally rare, with only five kindreds reported worldwide. Cardiac dysfunction, which can be life-threatening, is recognized in the disorder. Here we describe the clinical, metabolic, ophthalmic, and cardiac findings in a 9-year-old boy harboring a biallelic THRB mutation (R243Q (...) and cardiac function. A combination of antithyroid drug and TRIAC therapy may prevent thyrotoxic cardiomyopathy and its decompensation in homozygous or even heterozygous RTHβ in which life-threatening hyperthyroid features predominate.

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

7. Increased Risk of Antithyroid Drugs Agranulocytosis Associated with Amiodarone-induced Thyrotoxicosis: a Population-based Cohort Study. (PubMed)

Increased Risk of Antithyroid Drugs Agranulocytosis Associated with Amiodarone-induced Thyrotoxicosis: a Population-based Cohort Study. Agranulocytosis occurs in 0.2-0.5% of patients treated with the antithyroid drugs (ATDs) methimazole and propylthiouracil. The objectives of this study were to evaluate the risk of ATD-related agranulocytosis in patients with amiodarone-induced thyrotoxicosis (AIT), and to compare it with the agranulocytosis risk in patients with thyrotoxicosis due to other

Full Text available with Trip Pro

2019 Thyroid

8. Impaired quality of life after radioiodine therapy compared with antithyroid drugs or surgical treatment for Graves' hyperthyroidism. A long-term follow-up with ThyPRO and SF-36. (PubMed)

Impaired quality of life after radioiodine therapy compared with antithyroid drugs or surgical treatment for Graves' hyperthyroidism. A long-term follow-up with ThyPRO and SF-36. Hyperthyroidism is known to have a significant impact on quality of life (QoL), at least in the short term. The purpose of the present study was to assess QoL in patients 6-10 years after treatment for Graves' disease (GD) with radioiodine (RAI) compared to those treated with thyroidectomy or antithyroid drugs (ATD

2019 Thyroid

9. Maternal thyroid function, use of antithyroid drugs in early pregnancy and birth defects. (PubMed)

Maternal thyroid function, use of antithyroid drugs in early pregnancy and birth defects. Antithyroid drug (ATD) therapy in early pregnancy is associated with birth defects, but more data are needed to substantiate the risk associated with different types of ATD. Furthermore, the role of abnormal maternal thyroid function per se remains unclarified.To evaluate the risk of birth defects associated with the use of ATD in an extended nationwide cohort and the role of abnormal maternal thyroid

2019 Journal of Clinical Endocrinology and Metabolism

10. Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan. (PubMed)

Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan. Background: The prevalence of antithyroid drug (ATD)-related drug-induced liver injury (DILI) has been reported to vary among patients in several countries. The purpose of this study was to summarize the prevalence of liver injury induced by ATD and to determine the actual prevalence of severe liver injury. Methods: The medical records of 18,558 patients who were newly (...) years (range 10-82 years). Nine of 461 patients had severe DILI with both drugs. The total prevalence of severe DILI in this study was 2.5%, and the prevalence of DILI by drug was 1.4% with metimazole (MMI) (n = 198) and 6.3% with propylthiouracil (PTU) (n = 272) (p < 0.001). The prevalence of the most severe ATD-related DILI was 0.22% (n = 40), and the prevalence for each drug was 0.08% with MMI (n = 11) and 0.68% with PTU (n = 29). The median time to DILI development was 30 days (range 7-314 days

2019 Thyroid

11. Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study. (PubMed)

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study. Purpose. To study predictors of attaining (part 1) and sustaining (part 2) remission in patients with Graves' hyperthyroidism (GH) treated with antithyroid drugs (ATD). Methods. In the prospective first part, the included patients were treated with ATD until a prespecified definition of remission (thyrotropin > 0.4 mU/L and TSH-receptor antibodies (TRAb) ≤ 1. 0

2019 Journal of thyroid research Controlled trial quality: uncertain

12. ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later (PubMed)

ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later The thionamide antithyroid drugs were discovered in large part following serendipitous observations by a number of investigators in the 1940s who found that sulfhydryl-containing compounds were goitrogenic in animals. This prompted Prof. Edwin B Astwood to pioneer the use of these compounds to treat hyperthyroidism in the early 1940s and to develop the more potent and less toxic drugs that are used today. Despite their simple (...) molecular structure and ease of use, many uncertainties remain, including their mechanism(s) of action, clinical role, optimal use in pregnancy and the prediction and prevention of rare but potentially life-threatening adverse reactions. In this review, we summarize the history of the development of these drugs and outline their current role in the clinical management of patients with hyperthyroidism.© 2018 European Society of Endocrinology

Full Text available with Trip Pro

2018 European Journal of Endocrinology

13. Association of HLA-B∗38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients (PubMed)

Association of HLA-B∗38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients HLA-B∗38:02 has been shown to be associated with antithyroid drug-induced agranulocytosis in Asian patients.HLA-B∗38:02 was analyzed by sequence-based typing in 21 patients who developed antithyroid drug-induced agranulocytosis and in 81 controls.Frequency of HLA-B∗38:02 was 52.4% in agranulocytosis patients compared to 3.7% in controls (OR = 28.6, 95% CI = 6.8-120.2).HLA-B∗38:02 (...) is a significant risk factor for agranulocytosis in Kinh Vietnamese patients treated with antithyroid drug.

Full Text available with Trip Pro

2018 International journal of endocrinology

14. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves’ ophthalmopathy – a 1-year follow-up: study protocol for a randomized controlled trial (PubMed)

Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves’ ophthalmopathy – a 1-year follow-up: study protocol for a randomized controlled trial Graves' disease (GD) is characterized by thyrotoxicosis and goiter and arises through circulating autoantibodies that bind to, and stimulate, the thyroid hormone receptor (TSHR). A temporal relation between the onset of hyperthyroidism and the onset of ophthalmopathy, a common extrathyroidal (...) manifestation, has been demonstrated. Graves' ophthalmopathy (GO) is typically characterized by an inflammation and expansion of the extraocular muscles and an increase in retroorbital fat. There are currently three forms of therapies offered for hyperthyroidism caused by Graves' disease: antithyroid drugs (ATD) (thionamides), radioiodine ablation (RAI) and thyroidectomy (Tx). To date, there is no clear recommendation on the treatment of Graves' disease and GO, mainly due to the individuality of the disease

Full Text available with Trip Pro

2018 Trials

15. Timing of shift in antithyroid drug therapy and birth defects. (PubMed)

Timing of shift in antithyroid drug therapy and birth defects. 30458113 2019 01 23 1557-9077 29 1 2019 Jan Thyroid : official journal of the American Thyroid Association Thyroid Timing of Shift in Antithyroid Drug Therapy and Birth Defects. 155-156 10.1089/thy.2018.0621 Andersen Stine Linding SL 1 Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark. 2 Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. Andersen Stig S 3 Department

2018 Thyroid

16. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction. (PubMed)

Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction. A relationship between iodine intake and the effectiveness of antithyroid drug (ATD) therapy for Graves' disease (GD) has been suggested, and strict restriction of iodine intake has been tried in the treatment of GD in some studies. However, it is unclear whether dietary iodine supplementation improves the prognosis of ATD therapy for GD (...) . This study aimed to clarify whether optimal iodine supplementation during antithyroid drug therapy for GD is associated with lower recurrence rates than iodine restriction.This was a prospective randomized trial of newly diagnosed patients with GD. Patients with newly diagnosed GD were recruited. After ATD therapy and strict dietary iodine restriction for 1 month, patients (n = 459) were randomly assigned to iodine-supplemented and iodine-restricted groups. After exclusion, 405 patients finally completed

2018 Clinical endocrinology Controlled trial quality: uncertain

17. Radioiodine therapy versus antithyroid medications for Graves' disease. (PubMed)

(young/older methimazole group) and for radioiodine treatment USD 1862. Costs for patients with relapse and methimazole treatment were USD 2284/1972 (young/older methimazole group) and for radioiodine treatment USD 2760.The only antithyroid drug investigated in the two included trials was methimazole, which might limit the applicability of our findings with regard to other compounds such as propylthiouracil. Results from two RCTs suggest that radioiodine treatment is associated with an increased risk (...) Radioiodine therapy versus antithyroid medications for Graves' disease. Graves' disease is the most common cause of hyperthyroidism. Both antithyroid medications and radioiodine are commonly used treatments but their frequency of use varies between regions and countries. Despite the commonness of the diagnosis, any possible differences between the two treatments with respect to long-term outcomes remain unknown.To assess the effects of radioiodine therapy versus antithyroid medications

2016 Cochrane

18. Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. (PubMed)

Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. Antithyroid drugs (ATDs) may have teratogenic effects, but more evidence is needed on the risk and types of birth defects after the use of methimazole (MMI) and propylthiouracil (PTU). This study aimed to evaluate the association between the use of ATDs in early pregnancy and birth defects.Swedish nationwide register-based cohort study.The study included 684 340 children live-born in Sweden from 2006

Full Text available with Trip Pro

2017 European Journal of Endocrinology

19. Long-term antithyroid drug treatment: a systematic review and meta-analysis. (PubMed)

Long-term antithyroid drug treatment: a systematic review and meta-analysis. Several studies have reported inconsistent findings on the advantages and disadvantages of long-term treatment with antithyroid drugs (ATD). A systematic review and meta-analysis was undertaken to clarify the numerous aspects of long-term treatment with ATD.Medline and the Cochrane Library for trials published between 1950 and May 2016 were systematically searched. Studies containing data for long-term (>24 months) ATD

2017 Thyroid : official journal of the American Thyroid Association

20. MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. (PubMed)

MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Graves' disease is an autoimmune disorder. It is the leading cause of hyperthyroidism, but is rare in children. Patients are initially managed with antithyroid drugs (ATDs), such as methimazole/carbimazole. A major disadvantage of treatment with ATD is the high risk of relapse, exceeding 70% of children treated for duration of 2 years, and the potential major side effects (...) of the drug reported in exceptional cases. The major advantage of ATD treatment is that normal homeostasis of the hypothalamus-pituitary-thyroid axis may be restored, with periods of drug treatment followed by freedom from medical intervention achieved in approximately 40-50% of cases after prolonged treatment with ATD, for several years, in recent studies. Alternative ablative treatments such as radioactive iodine and, less frequently and mostly in cases of very high volume goiters or in children under

Full Text available with Trip Pro

2017 European Journal of Endocrinology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>